Aaron Cox, Chief Financial Officer of Lakefront Biotherapeutics, stated: "As part of the transaction announced with Gilead in March 2026, we secured the option to repurchase up to $150m in shares, subject to having sufficient distributable reserves. We are pleased to initiate this process with an initial €50m program."

Following the announcement, analysts at KBC Securities reiterated their accumulate rating on the stock with a price target of €37, representing an upside potential of approximately 52%.